Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Minerva Neurosciences (NERV) Research & Development (2016 - 2026)

Minerva Neurosciences filings provide 2 years of Research & Development readings, the most recent being $18.7 million for Q4 2021.

  • On a quarterly basis, Research & Development rose 427.87% to $18.7 million in Q4 2021 year-over-year; TTM through Dec 2021 was $32.0 million, a 45.37% increase, with the full-year FY2025 number at $5.8 million, down 51.6% from a year prior.
  • Research & Development hit $18.7 million in Q4 2021 for Minerva Neurosciences, up from $4.5 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $18.7 million in Q4 2021 to a low of $3.3 million in Q1 2021.